Vanguard Group
TRAW icon

Vanguard Group’s Traws Pharma TRAW Stock Holding History

Vanguard Group’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$98.6K Hold
87,259
– – ﹤0.01% 4180
2025
Q3 		$161K Buy
87,259
+74,086
+562% +$121K ﹤0.01% 4159
2025
Q2 		$19.5K Hold
13,173
– – ﹤0.01% 4250
2025
Q1 		$30.3K Buy
13,173
+32
+0.2% +$166 ﹤0.01% 4226
2024
Q4 		$117K Sell
13,141
-13,581
-51% -$75.6K ﹤0.01% 4156
2024
Q3 		$157K Sell
26,722
-1,555
-5% -$14.1K ﹤0.01% 4158
2024
Q2 		$316K Sell
28,277
-68
-0.2% -$1.1K ﹤0.01% 4092
2024
Q1 		$716K Hold
28,345
– – ﹤0.01% 3914
2023
Q4 		$528K Hold
28,345
– – ﹤0.01% 4015
2023
Q3 		$504K Hold
28,345
– – ﹤0.01% 4050
2023
Q2 		$836K Buy
28,345
+3,413
+14% +$91.8K ﹤0.01% 3954
2023
Q1 		$455K Hold
24,932
– – ﹤0.01% 4146
2022
Q4 		$402K Buy
24,932
+14
+0.1% +$264 ﹤0.01% 4159
2022
Q3 		$549K Buy
24,918
+4,438
+22% +$134K ﹤0.01% 4185
2022
Q2 		$676K Buy
20,480
+1,135
+6% +$38.3K ﹤0.01% 4207
2022
Q1 		$890K Sell
19,345
-14,509
-43% -$673K ﹤0.01% 4244
2021
Q4 		$2.16M Sell
33,854
-542
-2% -$43.6K ﹤0.01% 4003
2021
Q3 		$3.29M Buy
34,396
+7,171
+26% +$924K ﹤0.01% 3880
2021
Q2 		$4.72M Sell
27,225
-877
-3% -$198K ﹤0.01% 3639
2021
Q1 		$10.5M Buy
28,102
+6,073
+28% +$2.29M ﹤0.01% 3113
2020
Q4 		$3.85M Buy
22,029
+3,541
+19% +$411K ﹤0.01% 3475
2020
Q3 		$1.94M Buy
18,488
+2,218
+14% +$548K ﹤0.01% 3498
2020
Q2 		$3.45M Buy
16,270
+10,130
+165% +$1.55M ﹤0.01% 3256
2020
Q1 		$698K Buy
6,140
+5,938
+2,940% +$932K ﹤0.01% 3592
2019
Q4 		$29K Sell
202
-27
-12% -$5.04K ﹤0.01% 4072
2019
Q3 		$73K Buy
229
+53
+30% +$45.6K ﹤0.01% 4056
2019
Q2 		$189K Buy
176
+67
+61% +$92.3K ﹤0.01% 3989
2019
Q1 		$135K Hold
109
– – ﹤0.01% 3979
2018
Q4 		$86K Sell
109
-262
-71% -$447K ﹤0.01% 4013
2018
Q3 		$1.02M Buy
371
+269
+264% +$686K ﹤0.01% 3716
2018
Q2 		$232K Buy
102
+41
+67% +$119K ﹤0.01% 3952
2018
Q1 		$287K Buy
61
+33
+118% +$236K ﹤0.01% 3900
2017
Q4 		$236K Buy
28
+12
+75% +$124K ﹤0.01% 3902
2017
Q3 		$155K Hold
16
– – ﹤0.01% 3950
2017
Q2 		$190K Buy
16
+6
+60% +$74.5K ﹤0.01% 3913
2017
Q1 		$169K Buy
10
+2
+25% +$31K ﹤0.01% 3930
2016
Q4 		$103K Buy
8
+4
+100% +$59.4K ﹤0.01% 3970
2016
Q3 		$60K Sell
4
-2
-33% -$40.8K ﹤0.01% 4020
2016
Q2 		$211K Hold
6
– – ﹤0.01% 3936
2016
Q1 		$184K Hold
6
– – ﹤0.01% 3967
2015
Q4 		$303K Buy
6
+1
+20% +$74.1K ﹤0.01% 3940
2015
Q3 		$400K Hold
5
– – ﹤0.01% 3914
2015
Q2 		$690K Hold
5
– – ﹤0.01% 3773
2015
Q1 		$701K Hold
5
– – ﹤0.01% 3729
2014
Q4 		$870K Buy
5
+1
+25% +$245K ﹤0.01% 3571
2014
Q3 		$1.07M Hold
4
– – ﹤0.01% 3486
2014
Q2 		$1.29M Buy
4
+1
+33% +$295K ﹤0.01% 3419
2014
Q1 		$991K Buy
3
+2
+200% +$1.2M ﹤0.01% 3460
2013
Q4 		$920K Hold
1
– – ﹤0.01% 3439
2013
Q3 		$2.11M Buy
+1
New +$1.43M ﹤0.01% 3107

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's TRAW Position: Q4 2025 in Review

Vanguard Group held its Traws Pharma (TRAW) position steady in Q4 2025 at 87,259 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4180.

Vanguard Group first reported a position in TRAW in Q3 2013 and has held it in 50 quarters since. The position peaked at $10.5M in Q1 2021. 22 funds tracked by Wall St. Rank hold TRAW as of Q4 2025.

  • Vanguard Group held 87,259 shares of Traws Pharma worth $98.6K as of Q4 2025.
  • Vanguard Group left its Traws Pharma share count unchanged in Q4 2025.
  • Traws Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4180 holding.
  • Vanguard Group first reported a position in Traws Pharma in Q3 2013 and has held it in 50 quarters since.
  • Vanguard Group's Traws Pharma position peaked at $10.5M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.